144 related articles for article (PubMed ID: 2411501)
1. Influence of L-DOPA/carbidopa on pattern reversal VEP: behavioural difference in primary and secondary parkinsonism.
Sollazzo D
Electroencephalogr Clin Neurophysiol; 1985 Oct; 61(4):236-42. PubMed ID: 2411501
[TBL] [Abstract][Full Text] [Related]
2. Acute effects of levodopa plus carbidopa on evoked potentials in Parkinson's disease.
Cosi V; Romani A; Callieco R; Zerbi F
Boll Soc Ital Biol Sper; 1984 Mar; 60(3):603-9. PubMed ID: 6712828
[TBL] [Abstract][Full Text] [Related]
3. Effect of L-dopa on visual evoked potential in patients with Parkinson's disease.
Bhaskar PA; Vanchilingam S; Bhaskar EA; Devaprabhu A; Ganesan RA
Neurology; 1986 Aug; 36(8):1119-21. PubMed ID: 3736880
[TBL] [Abstract][Full Text] [Related]
4. Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans.
Onofrj M; Ghilardi MF; Basciani M; Gambi D
J Neurol Neurosurg Psychiatry; 1986 Oct; 49(10):1150-9. PubMed ID: 3023551
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic deficiency and delayed visual evoked potentials in humans.
Bodis-Wollner I; Yahr MD; Mylin L; Thornton J
Ann Neurol; 1982 May; 11(5):478-83. PubMed ID: 6125124
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Brannan T; Yahr MD
Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
[TBL] [Abstract][Full Text] [Related]
8. [Somatosensory evoked potentials in patients with parkinsonism during L-dopa decarboxylase inhibitor treatment].
Koziel H; Kuran W; Zakrzewska F
Neurol Neurochir Pol; 1977; 11(1):73-80. PubMed ID: 840365
[No Abstract] [Full Text] [Related]
9. Visual evoked potentials (VEPs) in Parkinson's disease: correlation of pattern VEPs abnormality with dementia.
Okuda B; Tachibana H; Kawabata K; Takeda M; Sugita M
Alzheimer Dis Assoc Disord; 1995; 9(2):68-72. PubMed ID: 7662325
[TBL] [Abstract][Full Text] [Related]
10. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
[TBL] [Abstract][Full Text] [Related]
11. Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials.
Peppe A; Stanzione P; Pierelli F; De Angelis D; Pierantozzi M; Bernardi G
Neurology; 1995 Jun; 45(6):1144-8. PubMed ID: 7783879
[TBL] [Abstract][Full Text] [Related]
12. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study.
Hoehn MM
Arch Neurol; 1980 Mar; 37(3):146-9. PubMed ID: 7356419
[TBL] [Abstract][Full Text] [Related]
13. A comparison of levodopa treatment and task demands on visual evoked potentials in hemi-parkinsonism.
Mintz M; Tomer R; Radwan H; Myslobodsky MS
Psychiatry Res; 1982 Apr; 6(2):245-51. PubMed ID: 6953463
[TBL] [Abstract][Full Text] [Related]
14. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
[TBL] [Abstract][Full Text] [Related]
15. Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
Rappelli A; Glorioso N; Tedde R; Dessi'-Fulgheri P; Monaco F
J Neurol Neurosurg Psychiatry; 1978 Oct; 41(10):915-8. PubMed ID: 731241
[TBL] [Abstract][Full Text] [Related]
16. Electroencephalographic lateralization, clinical correlates and pharmacological response in untreated Parkinson's disease.
Mostile G; Nicoletti A; Dibilio V; Luca A; Pappalardo I; Giuliano L; Cicero CE; Sciacca G; Raciti L; Contrafatto D; Bruno E; Sofia V; Zappia M
Parkinsonism Relat Disord; 2015 Aug; 21(8):948-53. PubMed ID: 26096796
[TBL] [Abstract][Full Text] [Related]
17. Combined use of benserazide and carbidopa in Parkinson's disease.
Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
[TBL] [Abstract][Full Text] [Related]
18. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
19. Effect of levodopa on the human pattern electroretinogram and pattern visual evoked potentials.
Gottlob I; Weghaupt H; Vass C; Auff E
Graefes Arch Clin Exp Ophthalmol; 1989; 227(5):421-7. PubMed ID: 2806927
[TBL] [Abstract][Full Text] [Related]
20. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
